NasdaqGM:SMMTBiotechs
Did Updated Survival Data Just Shift Summit Therapeutics (SMMT) Investment Narrative?
Summit Therapeutics reported updated Phase III HARMONi data for ivonescimab plus chemotherapy in EGFR mutated non squamous NSCLC, with overall survival and safety results remaining consistent and favorable across Asian and western patients, and forming the core of its ongoing U.S. BLA review.
The repeated overall survival hazard ratio of 0.76 across the global population and western subgroup highlights how ivonescimab’s effect looks regionally aligned. This matters for Summit Therapeutics as...